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Summary. Advances in scientific techniques have
provided researchers with exceptional new opportunities
to identify and monitor changes between different cancer
types, during different stages of progression, between
individual tumor cells and in the surrounding stroma.
The wealth of information that can be obtained from
new scientific techniques places additional requirements
on the conventional cancer models. New models that
could be used to rapidly access the (potential) functional
importance of newly identified (epi)genetic and
proteomic changes and test the efficacy on emerging
(combinatorial) therapies are desperately required. The
distinctive characteristics of zebrafish are progressively
being applied to create more relevant models of human
diseases. Zebrafish embryos provide a powerful tool to
develop functional cancer models. This is a tool that can
be used from drug discovery and development to
assessment of drug toxicity. This review will summarise
the use of zebrafish xenograft models to study human
cancers, and discuss the benefits and limitations of these
models. 
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Introduction
Cancer is a genetic disease (Hanahan and Weinberg,
2011). Cancer is a prominent cause of human morbidity
and mortality (McGuire, 2016). Researchers face a great
challenge in trying to understand the (epi)genetic basis
of this disease, the role of tumor heterogeneity and the
interactions between stroma and tumor cells, the
mechanisms that underlie why certain patients do or do
not respond to therapy, and how to prevent therapy
resistance. In order to study the biochemical pathways in
cancer cells, researchers use animal and human cancer
cell lines in vitro and in vivo. The most common in vivo
cancer model is that of the rodent, specifically the
mouse: 95% of its genetic material is similar to humans
(Mouse Genome Sequencing et al., 2002). There are
many short-comings to the mouse model and a search is
on to find alternatives. One such in vivo model is the
zebrafish (Danio rerio), which is proving to be an
elegant model to study human cancer.
Murine models have revolutionised the study of
gene and protein function in vivo. The mouse model
allowed for the greater understanding of the molecular
pathways and mechanisms used by cancer cells (Frese
and Tuveson, 2007). New developments, such as
organoids, can allow for the testing of drugs on human
cancer cells in a mouse background (Sachs and Clevers,
2014). However, these studies need to be done in
immune-compromised mice, which do not allow for
efficient testing of immune system in the treatment
response. Moreover, testing of many (combinations of)
(epi)genetic changes and drugs on tumor initiation and
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progression quickly is difficult to archive in a mouse. 
What would be the ideal model for human cancer?
Simply put, a model that perfectly reflects the tumor and
its microenvironment. The criteria of an ideal model
includes the need to imitate the human tumor clonal
origin, as well as the histopathology of the tumor, and
the various stages of tumorigenesis (including metastasis
and recurrence). In addition, the ideal model should be
able to accommodate several mutations in specific genes
as well as alterations in specific pathways that are
known to be involved in human cancers and the genomic
instability that induces gross chromosomal aberrations.
This ideal should be useful in the testing of new
therapies and the identification of biomarkers. Moreover,
this model should be able to be used in high-throughput
screening. Furthermore, the drug response in the model
should accurately anticipate the results of clinical trials
(Hann and Balmain, 2001). Finding one model that
encompasses all of these traits will be impossible.
However, a model does not need to be to completely
faithful to the human disease equivalent for it to be
effective to address one particular aspect. For example,
in basic cancer research a simple model that is suitable
for high-throughput screening may be a better tool than a
highly complex model that contains parameters that are
not utilised. 
While the initial focus of zebrafish research was in
the field of developmental biology (Grunwald and Eisen,
2002), zebrafish made their debut splash as a cancer
model in the 1960s (Stanton, 1965). Although the last
common ancestor of fish and human is separated by more
than 400 million years, the biology of cancer in these two
organisms share many characteristics (Schartl, 2014),
both at the molecular level (Abouheif et al., 1997; Dodd
et al., 2000; Woods et al., 2000) and physiologically
(Lieschke et al., 2001; Weinstein, 2002; Guyon et al.,
2007; Kalueff et al., 2014). In addition, the architecture
and microenvironment of a tumor can be live monitored
in zebrafish cancer systems (Ignatius and Langenau,
2011). Zebrafish are prolific breeders, which reach sexual
maturity by 3 months. A lone female can produce up to
100 eggs in one session, and the eggs are fertilized
externally. They have a short life cycle; their major
organs are fully developed by 24 hours post fertilization
(HPF) and the larvae can be ready for experimental use
by 3 days post fertilization (DPF). The embryos are
transparent though to 7 DPF, and this can be prolonged
up to 14 DPF with the use of melanin synthesis inhibitors
(White et al., 2008). Zebrafish are also small and do not
require expensive food – they can be cost effective. It is
no surprise that zebrafish are considered a strong model
system for the study of human disease (Lieschke and
Currie, 2007; Pyati et al., 2007). This is especially true
for zebrafish embryos, as they have an immature immune
system, can be injected with human tumor cells, where
tumor growth, invasion and metastasis, and the interplay
with host cells can be easily examined.
This review will summarize the use of zebrafish
xenografts with human tumor cells. This review will
discuss the advances of genetic manipulation of the fish
to investigate different interactions of cancer cells, for
example with the microenvironment such as angio-
genesis and immune cells. We will also highlight the
different xenotransplantation approaches. Finally, some
of the benefits and limitations of using zebrafish
xenograft models will be discussed. This review will not
discuss spontaneous, drug induced, or transgenic cancer
models. Reviews that do cover these topics have been
authored by the Zon (White et al., 2013), and White
(White, 2015) groups.
Xenotransplantation
Xenotransplantation involves the transfer
(transplantation, implantation, or infusion) of one
species-specific tissue to another animal species. This
procedure has been used for many years in the study of
human cancer (Sharkey and Fogh, 1984; Cekanova and
Rathore, 2014). Xenograft experiments are commonly
done in mouse models, and have enabled the
examination of cancer cell proliferation, invasion
(Sanchez-Tillo et al., 2012), migration (van Marion et
al., 2016) and induction of tumor angiogenesis
(Carmeliet and Jain, 2000). Professor Edward Sausville,
has been quoted (Garber, 2006) as saying that “mouse
xenografts will remain the ‘gold standard’ in cancer drug
development.” But given restraints of time and cost, as
well as the complexity of a mouse system, it means that
it is not always practical to use mice. 
Zebrafish present a unique opportunity to extend the
knowledge gained from xenograft models. Zebrafish -
human xenotransplantation models are being utilized to
investigate a number of critical facets in tumor biology,
comprised of cancer cell growth (Haldi et al., 2006),
invasion (Naber et al., 2013; Yang et al., 2013),
induction of angiogenesis (Tobia et al., 2011; He et al.,
2012), metastasis (He et al., 2012; Drabsch et al., 2013;
van der Ent et al., 2014a), and identification of new
treatment strategies with translational values (Goessling
et al., 2007; Konantz et al., 2012; Ghotra et al., 2015;
Zoni et al., 2015; Mercatali et al., 2016). Most of these
investigations injected human cancer cells into early-
stage zebrafish embryos. This is due to 3 main
considerations: 
1) The adaptive immune system of a zebrafish has
not developed until 14 DPF (Renshaw and Trede, 2012).
The human cancer cells are thus able to survive, invade,
and metastasize when transferred into the embryonic
zebrafish. 
2) The transplanted cells in the transparent
embryonic zebrafish can be visualized easily (Ignatius
and Langenau, 2011). This is due to the use of
fluorescent labels. 
3) Human cells can communicate with the zebrafish
host (Tulotta et al., 2016). The intercommunication
between the cells of these two species is conserved. 
There are numerous sites of injection which have
been used regularly in the zebrafish cancer model (Fig.
674
Zebrafish as cancer cell models
1). These sites include the yolk sac, the Duct of Cuvier
and perivitelline space, and the hindbrain ventricle. 
Site of injection: Yolk sac
The yolk sac is an environment rich in nutrients and
suitable for the injected cells. Furthermore the yolk sac
is large and acellular, and the injected cells can grow,
migrate (if the cells are motile), and be easily monitored
post injection. These considerations have meant that the
most common site of injection is the yolk sac of 2 days
post fertilization (DPF) zebrafish (Veinotte et al., 2014). 
Researchers are using the yolk sac in more complex
ways than previously. Recent research injected a mix of
cancer cells and macrophages into the yolk sac of a
zebrafish embryo. This study showed that previous
exposure of macrophages to interleukin-6 (IL-6) and
tumor necrosis factor (TNF) enhances the metastatic
spread (Wang et al., 2015). 
Due to the unique properties of the zebrafish
embryo, it has allowed researchers to research human
hematopoietic stem cell trafficking in vivo (Staal et al.,
2016). The Staal group used the Casper tg(fli-GFP)
(described in further detail below) as recipients of
human CD34(+) red labelled cells. They successfully
visualized the differentiation of the transplanted human
hematopoietic stem cell CD34(+) cells, as well as
tracking them within the vasculature of the fish. 
Site of injection: Perivitelline space and the duct of cuvier 
Though the yolk sac is widely used for xenografts in
zebrafish, many groups prefer to study the later stages of
cancer progression by injecting the cancer cells into
either the perivitelline space (Nicoli and Presta, 2007),
or into the circulation via the Duct of Cuvier (He et al.,
2012; Zhang et al., 2012a,b; Drabsch et al., 2013; Naber
et al., 2013; de Boeck et al., 2016). Whereas injection of
fluorescently labelled cells in the perivitelline space
allows one to interrogate the efficiency of intravasation,
the entry of tumor cells directly into the blood
circulation allows the study of invasion and
micrometastasis (He et al., 2012). Dependent on the cell
line, different types of invasion (single cell or collective)
can be easily visualised. This is because the cells invade
into the tail fin. This xenograft model has contributed to
understanding how the transforming growth factor β
(TGF-β) pathway participates in the promotion of
invasion and metastasis of human tumor cells (Drabsch
and Ten Dijke, 2012; Zhang et al., 2012a,b; Drabsch et
al., 2013; Naber et al., 2013; de Boeck et al., 2016).
Furthermore, injecting into the perivitelline space was
used to demonstrate vascularization of the tumor,
localized tumour growth, and the involvement of
neutrophils and macrophages at the site of implantation
and the micrometastic region (He et al., 2012).
This method of xenotransplantation offers an
extraordinary prospect to live image the behaviour of
human cancer cells and their interaction with the innate
immune system in vivo (He et al., 2012; van der Ent et
al., 2014b; Tulotta et al., 2016). Although this approach
does not exactly recapitulate the initiation stages of a
human tumour, they do represent aspects of the invasive
spread of cancer, before and after the cancer cells have
entered the circulation. 
Site of injection: Hindbrain ventricle
There have been very few papers that have used the
hindbrain as a site for injection. Research done by Haldi
et al injected fluorescently labelled human melanoma
cells into the hindbrain ventricle of 2dpf zebrafish (Haldi
et al., 2006). This study demonstrated that masses from
melanoma cells participated in the process of
angiogenesis. Another study which used the hindbrain as
an injection site focused on glioblastoma - a highly
aggressive brain cancer. Glioblastoma cells implanted
into the yolk sac did display an invasive phenotype.
Interestingly, it was only when the glioblastoma cells
were injected into the hindbrain ventricle these cells
started to invade. This study makes evident that the
location of xenografts is an important factor when
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Fig. 1. Common Sites of Injection.
Shown are the most commonly used
injection sites for xenotransplantation
of a zebrafish during different stages
of development. A. 256-cell Stage.
The yolk sac (yellow) is the most common site of injection. B. 2 DPF zebrafish. The yolk sac (yellow) is the most common site for injection. This is
followed by the Duct of Cuvier (orange) and perivitelline space and the hindbrain (blue). The site of invasion in the tail fin is highlighted in green. C.
Juvenile Adult. The majority of xenografts occur within the intraperitoneal cavity.
designing in vivo experiments (Wehmas et al., 2016). 
Adult zebrafish
The studies so-far highlighted in this review have
used embryonic zebrafish hosts, and exploit the lack of
an adaptive immune system, thus avoiding rejection.
However, because of a recently created immunocompro-
mised Rag2 mutant line, rag2E450fs (Tang et al., 2014)
use of the adult zebrafish is now available for xenograft
studies. This transgenic line of fish is comparable to
Rag-deficient mice. The rag2E450fs zebrafish has
diminished amount of T cells and B cells, and the adult
rag2E450fs zebrafish has been shown to be a universal
recipient allograft cell transplantation. 
Adult transparent zebrafish are used extensively in
live in vivo imaging. For instance, to assess the
pharmacological effects of a small molecule MAP kinase
inhibtor (U0126) that targets the KRAS signalling
pathway in vivo, human pancreatic cancer cells were
xeno-transplanted into larval and adult zebrafish (Guo et
al., 2015). KRAS mutant cells displayed substantial
growth and migratory behaviour and invaded the
vasculature system of adult zebrafish. U0126 treatment
drastically reduced the proliferation and migration of the
cells. Also in adult zebrafish, xenografted leukaemia stem
cells (LSCs) from K562 cells were shown to proliferate in
vivo and after re-transplantation kept their cancer
properties (Zhang et al., 2014). This is important as the
current best method for defining a cancer stem cell is by
exhibiting a cell’s capacity to reconstitute a tumour in vivo
by serial transplantation (Baccelli and Trumpp, 2012). 
The results from these studies advocate the proposal
that xenotransplantation in zebrafish is a simple and
efficient tool to study a wide range of human cancers. 
Zebrafish lines and development
An important development that could be partnered
with xenotransplantation in order to research cancer cell
progression in a living environment is fluorescent
transgenic zebrafish reporter lines. Thousands of
zebrafish reporter lines have been made and may be
directly requested from the laboratories which generated
them. Another way to obtain a specific zebrafish line is
via public stock centres such as the Zebrafish
International Resource Center (ZIRC; http://zebrafish.
org/zirc/home/guide.php) and the European Zebrafish
Resource Center (EZRC; http://www.ezrc.kit.edu/). 
Some of the most widely used fluorescent reporter
lines available are included in Table 1. Of particular
importance are the tg(fli1a-eGFP), tg(mpx:eGFP), and
tg(mpeg1:eGFP). The tg(fli1a-eGFP) (Lawson and
Weinstein, 2002) has been widely used since its
inception in 2002. The fli1 promoter drives enhanced
GFP (eGFP) in endothelial cells. The zebrafish line
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Table 1. Frequently used fluorescent reporter transgenic zebrafish lines.
Zebrafish name Site of expression Reference
tg(0.8flt1:TFP)hu5333 arterial ISV Bussmann and Schulte-Merker, 2011; Bussmann et al., 2011
tg(−1696α1T:GFP) glia cells Goldman et al., 2001; Fausett et al., 2008
tg(5xUAS:cdh5-eGFP) endothelial cells Lenard et al., 2013
tg(-7.8gata4:GFP)ae3 endocardial and myocardial cells Heicklen-Klein and Evans, 2004; Heicklen-Klein et al., 2005
tg(acta2:mCherry) vascular smooth muscle cells Whitesell et al., 2014; Cetinkaya et al., 2016
tg(Brn3c:mGFP) dendritic cells Xiao et al., 2005
tg(dll4:eGFP) arterial cells Sacilotto et al., 2013
tg(dlx2b:EGFP) tooth and jaw germ cells Jackman and Stock, 2006; Aigler et al., 2014; Li et al., 2016
tg(ela:eGFP) pancreatic cells Wan et al., 2006; Calzolari et al., 2014; Navis and Bagnat, 2015
tg(fli-eGFP) endothelial and haematopoietic cells Lawson and Weinstein, 2002
tg(gata1:eGFP) blood cells Traver et al., 2003a,b
tg(gata2:eGFP) blood cells Long et al., 1997
tg(hsp70I:canotch3-eGFP) perivascular system Wang et al., 2014a,b
tg(hsp70l:shha-eGFP) retina Ertzer et al., 2007; Shen et al., 2013
tg(ins:GFP) insulin/pancreatic cells Huang et al., 2001; Li et al., 2009; Eames et al., 2013
tg(kdr.eGFP) angioblasts and endothelial precursor cells Cross et al., 2003; Jin et al., 2006
tg(l-fabp:DBP-EGFP) liver and vasculature Her et al., 2003a,b; Xie et al., 2010
tg(mpeg1:eGFP) macrophage lineage Ellett et al., 2011; Fang et al., 2011; Hall et al., 2013; Brudal et al., 2014, 2015
tg(mpx:eGFP) neutrophil lineage Renshaw et al., 2006; Ellett et al., 2011; Benard et al., 2012; 
Wang et al., 2014a; Shen et al., 2016
tg(my17:eGFP) myocardial cells Ho et al., 2007
tg(nkx2.3:efnb2a,myl7: eGFP) arterial cells Choe and Crump, 2015
tg(pax2a:GFP) optic vesicle and epibranchial placodes McCarroll et al., 2012; Aguillon et al., 2016; Juarez-Morales et al., 2016
tg(scl-α:dsRED) intermediate endothelial cells Zhen et al., 2013
tg(scl-β:d2eGFP) anterior-posterior endothelial cells Zhen et al., 2013
tg(Tie2:eGFP) endothelial cells Motoike et al., 2000
tgBAC(cdh5:Citrine) pan-endothelial cells Bussmann and Schulte-Merker, 2011; Bussmann et al., 2011
tgBAC(dll4:GAL4FF) endothelial cells Hermkens et al., 2015
tgBAC(flt4:Citrine) pan-endothelial cells Gordon et al., 2013
tg(mpx:eGFP), expresses GFP under the neutrophil-
specific myeloperoxidase promoter (Renshaw et al.,
2006). A macrophage-specific marker, mpeg1 was used
to drive eGFP in the zebrafish line tg(mpeg1:eGFP)
(Ellett et al., 2011). Combining transgenic lines of
zebrafish with transparent strains (ie Casper mutant
zebrafish) can enable the observation and analysis of the
interactions between cancer cell and its living
environment.
Targeted mutagenesis
A major breakthrough in zebrafish gene targeting
was the creation of synthetic transcription activator–like
effector nucleases (TALENs). TALENs can induce a
DNA break at virtually any desired spot in the genome
(Bogdanove and Voytas, 2011; Mussolino and
Cathomen, 2012; Zu et al., 2013). The use of TALENs
made it relatively simple to quickly create zebrafish
models that epitomize the flaws of biochemical pathway,
which contribute to various disease states. It was thought
that TALENs may be of use in drug discovery, as well as
the study of gene regulation. However, overall
difficulties with design, synthesis, and validation has
limited the widespread adoption of TALENs for routine
use (Gupta and Musunuru, 2014). The development of
the CRISPR/Cas9 system (Jinek et al., 2012; Cho et al.,
2013; Cong et al., 2013; Mali et al., 2013) as a new tool
used to edit the genome of living cells is revolutionising
molecular biology. 
CRISPR/Cas9 zebrafish
CRISPR/Cas9 is a new technology that has
profoundly changed targeted mutagenesis. It is based on
bacterial CRISPR (Clustered Regularly Interspaced
Short Palindromic Repeats) and CRISPR-associated
(Cas) genes, this method of genetic engineering
produces similar efficiencies to TALENs (Hwang et al.,
2013), but with a more robust and easier to use
technology. 
Briefly, the CRISPR/Cas9 technology consists of a
synthetic guide RNA (gRNA) and Cas9 protein that
work in concert with one another. The guide RNA is
designed to target the gene of interest. This synthetic
RNA guides the Cas9 (an endonuclease enzyme) to the
target DNA. Cas9 then acts as a molecular scissor and
cuts/edits that targeted DNA. A good review of the
general CRISPR/Cas9 techniques and history was
published earlier this year in Bioassays (Stella and
Montoya, 2016). In zebrafish, the CRISPR/Cas9
technology is operated by directly injecting the gRNA
and Cas9 mRNA into a one-cell stage embryo (Hruscha
et al., 2013; Hwang et al., 2013; Jao et al., 2013).
Multiple gene knock-out or large chromosomal deletions
are also possible with this technique (Xiao et al., 2013).
Of note, the mutations generated by the CRISPR/Cas9
technology are inherited by the next generation of
zebrafish - thus creating stable knock-out zebrafish lines
is theoretically rapid and simple (Talbot and Amacher,
2014). Knock-in strategies have also been developed
using the CRISPR/Cas9 system (Chang et al., 2013;
Hruscha et al., 2013; Auer et al., 2014a,b; Irion et al.,
2014; Kimura et al., 2014).
Earlier this year, Schier et al (McKenna et al., 2016)
used CRISPR/Cas9 in embryonic zebrafish in a
breakthrough study of developmental biology. They
developed a technique, GESTALT (Genome Editing of
Synthetic Target Arrays of Lineage Tracing), to
progressively introduce, and thus accumulate, a wide
range of mutations over several rounds of cell divisions.
The rate and pattern of the edits were analysed and by
sampling a large number of cells from various organs in
the zebrafish the group were able to monitor which cells
developed certain mutations over time. By analysing the
number and type of mutations in each cell, they were
able to conclude that most cells in the adult zebrafish’s
organs were derived from only a few embryonic
progenitors. GESTALT has immediate applications for
developmental biologists, but, this technique may also
be applied to cancer research, including a better
understanding of cancer initiation, and metastatic tumor
sites in relation to the initial tumor.
The importance of targeted mutagenesis in zebrafish
should not be ignored. Systems such as TALENS and
CRISPR/Cas9 will make it possible to modify the
microenvironment of the xenografted tumour.
Furthermore, by knocking-in certain genes (e.g. human
specific cytokines, receptors, and growth factors) it may
be possible to make the zebrafish more human. Such
humanization of a host environment has already been
used with mouse xenograft models (Wunderlich et al.,
2010; Willinger et al., 2011).
Interactions with the tumor microenvironment
Zebrafish xenotransplantation enables direct
observation of the communication between transplanted
cancer cells and their microenvironment. The developing
tumour has a microenvironment comprising of the tumor
stroma, blood vessels, inflammatory cells and an
assortment of other related tissue cells, as well as the
proliferating cancer cells (Whiteside, 2008). It is an
inimitable environment that develops as a result of the
interactions of the tumour with the host. It is the cancer
which coordinates the different events (molecular and
cellular) taking place in neighbouring tissues. A
limitation of studying the microenvironment is that the
communication mechanisms may not be active across
species. However, studies have shown that ligands
secreted by human tumor cells are active on zebrafish
host cells, and likewise, zebrafish ligands are active on
human cells (Lee et al., 2005; Topczewska et al., 2006;
Tulotta et al., 2016). 
One of the first studies to look at the tumor
microenvironment was performed by Lee et al. (2005).
Human metastatic melanoma cells that exhibited a
dedifferentiated phenotype were transplanted into
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blastula-stage embryos to understand the developmental
flexibility in response to signals from the micro-
environment. These human metastatic melanoma cells
survived, exhibited motility, and divided. These cells
maintained a state of dedifferentiation, did not form
tumors, nor integrate into the host organs. This is vastly
different from what is seen when normal human
melanocytes are transplanted - the normal cells were
frequently found disseminated throughout the
microenvironment of the skin, as expected. Thus, the
homing cues present in a zebrafish embryo can be
interpreted by normal human cells. Another study has
shown that host development is influenced by tumor
cells (Topczewska et al., 2006). Topczewska et al have
shown that an embryo transplanted with melanoma cells
will ectopically form the embryonic axis. Their analysis
discovered that inhibition of Nodal, a potent embryonic
morphogen that is secreted by melanoma cells, promoted
the return of a melanocytic phenotype in melanoma cells
and diminished the tumorigenicity of these cells. These
results not only suggested the importance of Nodal
signalling in the progression of melanoma, but provided
another promising therapeutic target for melanoma.
Recently, zebrafish were used to demonstrate cross-
communication between host and human ligands and
receptors. The conserved communication between
human breast cancer cells expressing CXCR4 and the
zebrafish host was exploited by the CXCR4 antagonist,
IT1t, and genetic inhibition of CXCR4 signalling.
Importantly, human cells expressing CXCR4 initiated
the early metastatic events by detecting similar zebrafish
ligands at the metastatic site. Both the tumor size and
spread were significantly reduced in the zebrafish
mutants of cxcl12 ligands, and direct activation of
human CXCR4 receptors on tumor cells by cxcl12 was
demonstrated (Tulotta et al., 2016).
Angiogenesis
Angiogenesis is an important promoter of tumor
growth, invasion, and metastases, and is a potential
therapeutic target (reviewed in Mittal et al., 2014). The
characteristics of the zebrafish can be exploited to
investigate tumor angiogenesis. Development of new
tools and techniques, including genetic manipulation and
in vivo imaging techniques has advanced the study of
angiogenesis in zebrafish models (Tobia et al., 2011).
Confocal microangiography is a technique for
visualizing patent blood vessels and has been used in
developing zebrafish (Cheng et al., 2001). Furthermore,
imaging chambers have been developed to deliver the
continuous circulation of warm oxygenated aqueous
media (Kamei and Weinstein, 2005). This chamber has
been used on tg(fli1a-eGFP) zebrafish for 5 days of
multiphoton time-lapse imaging to visualise the
developing blood vessels in the body. This technique did
not interfere with development or viability, nor was there
evidence of strength reduction of the circulatory flow. 
Recently, a group looked for old drugs with
antiangiogenic activity using the zebrafish model (Zhu
et al., 2016). The U.S. Drug Collection Library was
screened in the transgenic tg(fli1a-eGFP) zebrafish line
and 11 old drugs with antiangiogenic activity were
identified. One drug, Closantel, was verified as having
antiangiogenic activity in zebrafish by examining the
intersegmental and subintestinal vessels. Furthermore,
Closantel significantly repressed the growth of
xenotransplanted human cancer cell lines, in a dose-
dependent manner. The study used human lymphoma,
cervical cancer, pancreatic cancer, and liver cancer
cells.
Another recent study used the zebrafish model to
investigate glioma stem cells (GSCs) - looking at tumor
angiogenesis, invasion, and proliferation (Yang et al.,
2014). The researchers determined that some previously
verified anti-angiogenic agents repressed xenografted-
GSCs induced angiogenesis. Nordy, the synthetic dl-
nordihydroguaiaretic acid compound (dl-NDGA), was
further analysed and was shown to reduce GSCs
invasion and proliferation via the regulation of the
arachidonate 5-lipoxygenase (Alox-5) pathway.
Interestingly, an enhanced suppression of GSC-induced-
angiogenesis can be achieved through the combination
of Nordy and a vascular endothelial growth factor
(VEGF) inhibitor. 
The zebrafish/tumor xenograft angiogenesis assay
has been used to not only look at anti- angiogenic drugs,
but also microRNAs (Chiavacci et al., 2015). A prostate
cancer cell line, DU-145, has been transfected with four
microRNAs responsive to both anti- and pro-angiogenic
stimuli. After transfection, the DU-145 cells were
transplanted into tg(Kdrl:eGFP)s843 zebrafish
embryos, near the developing subintestinal vessels. The
tg(Kdrl:eGFP)s843 line of zebrafish have been used
previously in the study of vascular development (Jin et
al., 2005). At 72 h post-fertilization the GFP-positive
vessels permeated through the graft of DU-145
transfected with 3 of the microRNAs. However, vessel
formation and tumor cell invasion was inhibited with
the DU-145 cells transfected with remaining
microRNA. These results show that the zebrafish/tumor
xenograft is a model that is useful for the study of
angiogenesis. This model identified the microRNAs
needed to suppress the release of angiogenic growth
factors by tumor cells.
Syngeneic zebrafish
Syngeneic zebrafish have greatly assisted with tumor
transplantation studies (Mizgireuv and Revskoy, 2006,
2010; Smith et al., 2010). Syngeneic, or allograft,
models were developed over 50 years ago as a murine
tumour model. Syngeneic models retain an intact
immune system, and are therefore exceptionally relevant
for studies of immunologically-based targeted therapies
(Dranoff, 2012). Of note, syngeneic zebrafish have been
used to study self-renewing cancer cells - the only cell
types within a tumor that have an unlimited ability to
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promote cancer growth. The hypothesis underlying these
experiments is: targeting self-renewing cells will impede
tumor progression and prevent relapse, thus bettering the
patient’s prognosis (Zhou et al., 2009). The most
frequent way to establish the incidence of self-renewing
cells within a tumor is with a limiting dilution cell
transplantation assay (Dick et al., 1997; Tatekawa et al.,
2006). Briefly, the cancer cells are xenotransplanted into
several host animals at increasing doses. The ratio of
animals that develop tumours are used to gauge the
number of self-renewing cells from the original tumor
sample. Such a large scale experiment involving mice is
expensive, thus most experiments on limiting dilution
assays use 10-15 mice (Blackburn et al., 2011). A
method has been developed where fluorescently labelled
cancer cells can be transplanted into adult fish in order to
determine the number of self-renewing cells (Blackburn
et al., 2011). T-cell acute lymphoblastic leukaemia was
provided as the example, although the protocol can be
adapted to ascertain the number of self-renewing cells
using any cancer model in the zebrafish. To date, this
model has been used in T-cell acute lymphoblastic
leukaemia (Smith et al., 2010) and rhabdomyosarcoma
(Ignatius et al., 2012). Importantly, this model has been
successfully used to transplant single cells (Smith et al.,
2010). This model is perfect for limiting dilution
transplantation assays, as the cancer cells do not need to
undergo adaption for growth in a foreign micro-
environment, which could underestimate the frequency
of cell self-renewal (Kelly et al., 2007; Rosen and
Jordan, 2009). 
Limitations
The characteristics of the zebrafish xenograft model
provide a robust model for the study of human cancer,
but it is not without its limitations. As described earlier,
human and zebrafish genomes are similar (Schartl,
2014). However there are several cancer-associated
genes not expressed in zebrafish, including BRCA1,
p16, and IL6 (Howe et al., 2013). Not only does this
present a challenge when investigating the function of
these omitted genes, or their pathways, but the molecular
mechanisms linking the host to the cancer cells may not
be conserved either. Thus, the communication between
the human tumor cells and the zebrafish micro-
environment may be impacted. In the future, it may be
possible to humanize the zebrafish model. Mouse
models have been humanized for the study of infectious
disease (Brehm et al., 2013)
The zebrafish xenograft models also rely on an
impaired adaptive immune system. The absence of an
adaptive immune response is advantageous for the initial
transplantation and injection of human cells, this benefit
may become a limitation when translating the findings.
The adaptive immune cells can play an essential role in
the promotion or inhibition of cancer growth and
development and are also involved in the effects of
certain cancer treatments (Morgan, 2012; Gajewski et
al., 2013).
There are also limitations with the different
physiological requirements of using a zebrafish host and
human cancer cells. Zebrafish embryos are routinely
maintained at 28°C, and mammalian (including human)
cells are grown at 37°C. Maintaining mammalian cells at
28°C does not signify an optimal temperature for cell
growth and metabolism (Nicoli et al., 2007). As a
compromise, post-xenografted embryonic zebrafish are
housed at 32-35°C, with no obvious effects on zebrafish
development (Haldi et al., 2006). The increase in the
temperature of the zebrafish environment is hyper-
thermic and could be a source of stress (Rey et al.,
2015). In contrast, these temperature are considered
mildly hypothermic for mammalian cells. The effects of
mild hypothermia on the growth and metabolism of
Chinese hamster ovary (ICHO) cells was recently
studied (Vergara et al., 2014). Mammalian cells grown at
33°C showed a slower growth rate and differences in
metabolite production.
Finally, a xenograft does not portray the complexity
of a human tumor. The majority of human cancers take
years to grow. Tumor xenografts in a mouse model are
designed to grow in weeks, not years, and tumor
xenografts in an embryonic zebrafish model are
designed to grow in days, not weeks. There have been
several studies that analysed the considerable differences
between primary tumours and established cell lines. The
changes in the genomic stability and gene expression are
of particular importance (such as Lee et al., 2006), and
this is another limitation of using a model dependent on
cell lines. Although primary tumor cells can be
implanted into zebrafish, as described earlier, this is still




The evidence presented in this review show that the
zebrafish xenograft model offers many experimental
strengths that work well alongside other models. One
such model that is gaining momentum is the tumor
organoid. Tumor organoids are 3D cultures of tumor
cells that have self-organized and partially reproduce the
complexity of a tumor (van de Wetering et al., 2015).
Organoids fall in an area between the cancer cell lines
and patient derived tumor xenografts (PDTX) (Sachs
and Clevers, 2014). Current short-comings with
organoid cultures, such as lacking a microenvironment
are being addressed in the field (Huch and Koo, 2015).
One possible outcome of the organoid is a patient-
derived organoid that could be used to directly test the
drug sensitivity of the cancer as part of a personalised
treatment system (Clevers, 2016). Furthermore, novel
compounds could also be tested in a similar manner for
clinical research. Provided that drugs are optimized for
favourable pharmacokinetic and pharmacodynamics
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properties and have a good safety profile, we would
propose that when positive results on a particular
targeted therapy are obtained in both zebrafish xenograft
and tumor organoid models, this would provide
sufficient evidence to test the novel drug, (or
combination of drugs) in cancer patients as part of early
phase clinical trials.
Experimental automation and rapid high-resolution
imaging
Zebrafish xenotransplantation is progressing towards
enhanced experimental automation and fast high-
resolution imaging. Most xenotransplantation studies
manually inject the human cells into the zebrafish
embryo - which can be both laborious and technically
challenging. Methods have been developed where a
robot injects zebrafish embryos with a speed of up to
2000 embryos per hour with very high accuracy (Spaink
et al., 2013). Tests using this injection robot have used
the highly aggressive osteosarcoma cell lines SJSA-1,
osteosarcoma line L2792, the human prostate cells PC3
and LNCAP, and the melanoma cell line Mel57-VEGF.
The automated injection of cells into the yolk sac
occurred at the early pre-gastrulation stage zebrafish
(256-cell stage). Depending on the cancer cell type used,
Spaink et al have demonstrated the growth and invasion
of the xenografted cells into the tail fin. Continuing on
from this technique, an arrangement whereby the robotic
injection system is subsequently imaged via high-
throughput technologies (Ghotra et al., 2012) has been
used as a screen for many different mammalian cancer
cell lines in the zebrafish embryo model. The Complex
Object Parametric Analyzer and Sorter (COPAS, Union
Biosciences) is a flexible platform that is amenable to
the use of automatically sorting zebrafish embryos.
COPAS allows embryos to be selected on the basis of a
number of parameters, including length, optical density,
or fluorescence expression. Thus, COPAS can be
adapted to measure cancer cell proliferation. High-
throughput imaging systems can be used before and after
injection of fluorescent cells, and also in chemical
screens (Letamendia et al., 2012; Mathias et al., 2012).
This is possible because of the zebrafish’s small size,
transparency, number of offspring, and the ability to
grow in a liquid medium. The combination of an
automatic injection step with subsequent COPAS sorting
provides a mighty in vivo platform for the study of
human cancer. This automated approach could be used
to study patient-derived specimens. 
Preclinical and clinical applications
The zebrafish xenograft model can be used to test
experimental anticancer drugs. This is often quite simple
as the drugs need only be added to the fish water. For
example, quisinostat (a histone deacetylase inhibitor)
and MLN-4924 (a neddylation pathway inhibitor) were
assessed in a zebrafish uveal melanoma xenograft model
(van der Ent et al., 2014a). After these drugs were
directly added to the water of uveal melanoma-engrafted
embryos, the growth and invasion of the cells was
quantified using an automated confocal image analysis
platform. Both drugs were shown to block migration and
proliferation of the cancer cells.
Another excellent example used the CXCR4
inhibitor, IT1t (Tulotta et al., 2016). The CXCR4-
CXCL12 chemokine signalling axis helps to direct cell
migration in both physiological and pathological
conditions. As a potential target for the highly aggressive
triple-negative breast cancer subtype, Tulotta et al used a
zebrafish xenograft model and successfully blocked
early metastatic events with the CXCR4 inhibitor. Not
only did this study propose a pharmacological approach
to targeting triple-negative breast cancer, but also
validated the zebrafish xenograft model.
Primary human tumors, such as pancreatic, colon,
stomach (Marques et al., 2009), prostate (Bansal et al.,
2014) and primary leukaemia (Pruvot et al., 2011)
samples, were injected into zebrafish embryos, where
they proliferated and spread throughout the host.
Furthermore, a study was recently published describing
the development of a patient-derived xenograft of breast
cancer bone metastasis (Mercatali et al., 2016).
Zebrafish offer a key benefit when working with
precious biopsy samples compared to larger animal
models - typically zebrafish xenografts will require only
100–200 cells per zebrafish embryo. Furthermore,
because the engraftment does not require a lot of time, it
could be used as a tool for predicting patient response to
treatments. Potentially, tissues or cells from a patient
could be transplanted into hundreds of zebrafish
embryos and the response to the different available drug
treatments would be monitored. This would yield
constructive information regarding the most suitable
drugs administered for each individual patient.
Conclusions
The unique attributes of zebrafish are being
increasingly recognised in cancer biology. The zebrafish
model offers a fast, cheap, and powerful means of
investigating human cancer. Advances in genetic
manipulation, automated injection, and imaging
techniques have provided researchers with an
unprecedented opportunity to use zebrafish as a tool to
understand the many different types of human cancer
and their ability to proliferate, invade, metastasise, and
communicate with the microenvironment. The zebrafish
is not a complete model for human cancer - it has several
limitations. However, zebrafish xenografts can be used
to study the molecular pathways used in cancer cells.
Zebrafish embryos can be used to study the micro-
environment and angiogenesis. Furthermore, this model
can be utilised as a tool for predicting patient responses
to drug therapies, as well as being a simple model that is
suitable for high-throughput screening, and it works well
in conjunction with more complex models. The zebrafish
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proves a rapid, robust, and inexpensive model for the
study of human cancers.
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